At 3 months , compared with placebo , GM-CSF improved the physical functioning subscore of the SF-36 questionnaire by 11.4 ( 95 % CI , 6.7 to 16.1 ) vs 4.8 ( 95 % CI , -0.1 to 9.6 ) , with a mean difference in change for GM-CSF vs placebo of 7.5 ( 95 % CI , 1.0 to 14.0 ; P = .03 ) .